Takeda Sued By Ex-Employee For Innovation That Led To Vitamin Line
This article was originally published in PharmAsia News
Takeda Pharmaceuticals is being sued by a 73-year-old former researcher for nearly $541,000, saying the $433 the firm paid him for his role in developing a vitamin B1 derivative was not enough. The man's discovery of an efficient way to obtain a key substance from the B1 vitamin derivative, fursultiamine, led to Takeda's highly successful line of Alinamin products. Takeda reported nearly $6 billion in sales from the Alinamin product line. The man received an additional $162 after 1998 and the firm's new program of compensation for on-the-job inventions. Takeda said it has fulfilled its obligations to the researcher. (Click here for more - a subscription may be required
You may also be interested in...
Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.